Historical Valuation
Upstream Bio Inc (UPB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 999.61 is considered Overvalued compared with the five-year average of -5.71. The fair price of Upstream Bio Inc (UPB) is between 7.02 to 22.80 according to relative valuation methord. Compared to the current price of 29.75 USD , Upstream Bio Inc is Overvalued By 30.46%.
Relative Value
Fair Zone
7.02-22.80
Current Price：29.75
30.46%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Upstream Bio Inc (UPB) has a current Price-to-Book (P/B) ratio of 3.86. Compared to its 3-year average P/B ratio of 1.35 , the current P/B ratio is approximately 185.23% higher. Relative to its 5-year average P/B ratio of 1.35, the current P/B ratio is about 185.23% higher. Upstream Bio Inc (UPB) has a Forward Free Cash Flow (FCF) yield of approximately -8.38%. Compared to its 3-year average FCF yield of -11.20%, the current FCF yield is approximately -25.17% lower. Relative to its 5-year average FCF yield of -11.20% , the current FCF yield is about -25.17% lower.
P/B
Median3y
1.35
Median5y
1.35
FCF Yield
Median3y
-11.20
Median5y
-11.20
Competitors Valuation Multiple
AI Analysis for UPB
The average P/S ratio for UPB competitors is 266.28, providing a benchmark for relative valuation. Upstream Bio Inc Corp (UPB.O) exhibits a P/S ratio of 999.61, which is 275.39% above the industry average. Given its robust revenue growth of 12.52%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for UPB
1Y
3Y
5Y
Market capitalization of UPB increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of UPB in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is UPB currently overvalued or undervalued?
Upstream Bio Inc (UPB) is now in the Overvalued zone, suggesting that its current forward PS ratio of 999.61 is considered Overvalued compared with the five-year average of -5.71. The fair price of Upstream Bio Inc (UPB) is between 7.02 to 22.80 according to relative valuation methord. Compared to the current price of 29.75 USD , Upstream Bio Inc is Overvalued By 30.46% .
What is Upstream Bio Inc (UPB) fair value?
UPB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Upstream Bio Inc (UPB) is between 7.02 to 22.80 according to relative valuation methord.
How does UPB's valuation metrics compare to the industry average?
The average P/S ratio for UPB's competitors is 266.28, providing a benchmark for relative valuation. Upstream Bio Inc Corp (UPB) exhibits a P/S ratio of 999.61, which is 275.39% above the industry average. Given its robust revenue growth of 12.52%, this premium appears unsustainable.
What is the current P/B ratio for Upstream Bio Inc (UPB) as of Jan 11 2026?
As of Jan 11 2026, Upstream Bio Inc (UPB) has a P/B ratio of 3.86. This indicates that the market values UPB at 3.86 times its book value.
What is the current FCF Yield for Upstream Bio Inc (UPB) as of Jan 11 2026?
As of Jan 11 2026, Upstream Bio Inc (UPB) has a FCF Yield of -8.38%. This means that for every dollar of Upstream Bio Inc’s market capitalization, the company generates -8.38 cents in free cash flow.
What is the current Forward P/E ratio for Upstream Bio Inc (UPB) as of Jan 11 2026?
As of Jan 11 2026, Upstream Bio Inc (UPB) has a Forward P/E ratio of -8.80. This means the market is willing to pay $-8.80 for every dollar of Upstream Bio Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Upstream Bio Inc (UPB) as of Jan 11 2026?
As of Jan 11 2026, Upstream Bio Inc (UPB) has a Forward P/S ratio of 999.61. This means the market is valuing UPB at $999.61 for every dollar of expected revenue over the next 12 months.